Evidence mapPaperPMID 41596256Full record

ReviewInternational journal of molecular sciences2026

Insights into Cardiomyocyte Regeneration from Screening and Transcriptomics Approaches.

Daniela T Fuller, Aaron H Wasserman, Ruya Liu

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The pathophysiological role of MiRNAs in heart failure.Frontiers in cardiovascular medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniela T FullerDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0002-5653-7849
Aaron H WassermanDepartment of Medicine, Michigan State University College of Human Medicine, East Lansing, MI 48824, USA.ORCID 0000-0002-0428-9089
Ruya LiuDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0003-1986-6800

Funding

INTERDISCIPLINARY TRAINING PROGRAM IN MUSCLE BIOLOGYT32AR007592 · UNIVERSITY OF MARYLAND BALTIMORE · 1996 to 2025
$2.3M
NHLBI NIH HHS R56 HL169267NIAMS NIH HHS T32 AR007592
6 · The paper itself

Abstract

Human adult cardiomyocytes (CMs) have limited regenerative capacity, posing a significant challenge in restoring cardiac function following substantial CM loss due to an acute ischemic event or chronic hemodynamic overload. Nearly half of patients show no improvement in left ventricular ejection fraction during recovery from acute myocardial infarction. At baseline, both humans and mice exhibit low but continuous cell turnover originating from the existing CMs. Moreover, myocardial infarction can induce endogenous CM cell cycling. Consequently, research has focused on identifying drivers of CM rejuvenation and proliferation from pre-existing CMs. High-throughput screening has facilitated the discovery of novel pro-proliferative targets through small molecules, microRNAs, and pathway-specific interventions. More recently, omics-based approaches such as single-nucleus RNA sequencing and spatial transcriptomics have expanded our understanding of cardiac cellular heterogeneity. The big-data strategies provide critical insights into why only a subset of CMs re-enter the cell cycle while most remain quiescent. In this review, we compare several high-throughput screening strategies used to identify novel targets for CM proliferation. We also summarize the benefits and limitations of various screening models-including zebrafish embryos, rodent CMs, human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), and cardiac organoids-underscoring the importance of integrating multiple systems to uncover new regenerative mechanisms. Further work is needed to identify translatable and safe targets capable of inducing functional CM expansion in clinical settings. By integrating high-throughput screening findings with insights into CM heterogeneity, this review provides a comprehensive framework for advancing cardiac regeneration research and guiding future therapeutic development.

Indexed as

Myocytes, CardiacRegenerationTranscriptomeAnimalsCell ProliferationGene Expression ProfilingHigh-Throughput Screening AssaysHumansInduced Pluripotent Stem Cellscardiac regenerationcell heterogeneitydedifferentiationhigh-throughput screeningproliferation

Identifiers

PMID41596256
PMCPMC12841096

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.